Verici DX: Result of General Meeting

Verici Dx PLC

27 October 2026

 

Verici Dx plc

(“Verici Dx” or the “Company”)

Result of General Meeting

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that at the General Meeting ("GM") held earlier today, all resolutions, as set out in the GM notice published on 9 October 2026, were duly passed on a poll.  Resolution 1 was passed as an ordinary resolution and Resolution 2 was passed as a special resolution.

The voting results of the GM were as follows:

Admission and Total Voting Rights

Application has been made to the London Stock Exchange for admission of the 2,567,000,000 Conditional Placing Shares and 124,999,983 WRAP Retail Offer Shares to trading on AIM (“Second Admission”). It is expected that Second Admission will become effective and that trading will commence in the Conditional Placing Shares and WRAP Retail Offer Shares at 8.00 a.m. on 28 October 2026.

Following Second Admission, the total issued share capital of the Company will consist of 6,662,311,370 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company will be 6,662,311,370. With effect from Second Admission, this figure may be used by Shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

The new Ordinary Shares will be fully paid and will rank pari passu in all respects with each other and with the existing Ordinary Shares of the Company.

Capitalised terms not defined in this statement have the same meaning as given to them in the Company's Circular dated 9 October 2026.

Enquiries:

Verici Dx

Verici Dx plc (AIM: VRCI) is a precision diagnostics company transforming care for transplant patients. The company combines transcriptomic analysis with proprietary tests with underlying technology based upon artificial intelligence to deliver predictive, actionable, data-driven intelligence that reflects the complexity and heterogeneity of transplant patients, enabling clinicians to optimize therapy, guide biopsy decisions, and stratify risk with greater confidence.

Operating at the intersection of laboratory and data science, Verici Dx develops complex models that the Company believes answer the clinical questions that matter most with clarity and precision. All commercially available tests are built to rigorous scientific standards, validated across inclusive, and real-world patient populations to ensure clinical relevance and reliability. Verici Dx’s lead product, Tutivia™, is a post-kidney transplant test focused on early detection of acute rejection.

The company is UK headquartered in Cardiff for the UK, and in Franklin, Tennessee for the U.S. For more information, please visit https://vericidx.com/ and follow us on LinkedIn.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.